Actively Recruiting
Active Surveillance for Bethesda IV Thyroid Nodules
Led by Christian Grønhøj Larsen · Updated on 2026-01-27
165
Participants Needed
1
Research Sites
365 weeks
Total Duration
On this page
Sponsors
C
Christian Grønhøj Larsen
Lead Sponsor
R
Rigshospitalet, Denmark
Collaborating Sponsor
AI-Summary
What this Trial Is About
The traditional surgical approach for Bethesda IV thyroid nodules burdens healthcare systems and patients with costs, perioperative morbidity, and potential long-term consequences of hemithyroidectomy, including hypothyroidism (requiring lifelong thyroid hormone replacement), nerve damage, infection, voice discomfort and postoperative bleeding. Moreover, patient-reported anxiety and reduced quality of life often follow surgery, regardless of benign final pathology. Conversely, surveillance strategies that include periodic ultrasound assessment, clinical examination, and patient education may reduce overtreatment, preserve thyroid function, and optimize resource utilization. This prospective cohort protocol seeks to address these gaps by systematically evaluating the safety, feasibility, patient experience, and clinicopathologic predictors of progression for Bethesda IV nodules \<2 cm managed with active surveillance. Our hypothesis is: In patients with thyroid nodules smaller than 2 cm and cytology consistent with Bethesda IV, active surveillance is a safe and feasible alternative to immediate surgery. We hypothesize that only a minority of patients will demonstrate clinically significant tumor progression or require surgical intervention within five years, and that prospective surveillance can prevent unnecessary thyroid operations without compromising patient safety or long-term outcomes. The primary aim of this study is to determine the proportion of patients with Bethesda IV thyroid nodules \<2 cm who undergo surgical intervention or experience disease progression over a 1-, 2- and 5 year AS period.
CONDITIONS
Official Title
Active Surveillance for Bethesda IV Thyroid Nodules
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age of 30 years or older
- A single thyroid nodule with follicular neoplasm or suspicious for follicular neoplasm (Bethesda category IV)
- Tumor size less than 2 cm in all dimensions
- EU-TIRADS 3 or 4 classification on ultrasound imaging
You will not qualify if you...
- EU-TIRADS 5 classification on ultrasound imaging
- Suspicion of spread of disease due to PET-positive lymph nodes, suspicious lymph nodes on ultrasound or CT scan, capsular invasion, irregular shape or margins, or extrathyroidal growth
- Tumor located in a high-risk area of the thyroid capsule with extension toward vessels, recurrent laryngeal nerve, or trachea
- Previous thyroid surgery
- Presence of hyperparathyroidism with ionized calcium above 1.32 mmol/L and PTH above 6 pmol/L
- Pregnancy
- Unable to provide informed consent
- Elevated calcitonin levels above normal
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Otolaryngology, Head and Neck SurgeryRigshospitalet
Copenhagen, Denmark, 2100
Actively Recruiting
Research Team
N
Nicoline Thorup, MD, PhD Fellow
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here